July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Applying Propensity Score in Assessing Association of Glaucoma Medication with Structural Progression
Author Affiliations & Notes
  • Mengfei Wu
    NYU Langone Medical Center, New York, New York, United States
    Departments of Population Health and Environmental Medicine, NYU School of Medicine, New York, New York, United States
  • Mengling Liu
    NYU Langone Medical Center, New York, New York, United States
    Departments of Population Health and Environmental Medicine, NYU School of Medicine, New York, New York, United States
  • Katie Lucy
    NYU Langone Medical Center, New York, New York, United States
  • Hiroshi Ishikawa
    NYU Langone Medical Center, New York, New York, United States
  • Joel S Schuman
    NYU Langone Medical Center, New York, New York, United States
  • Gadi Wollstein
    NYU Langone Medical Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   Mengfei Wu, None; Mengling Liu, None; Katie Lucy, None; Hiroshi Ishikawa, None; Joel Schuman, Zeiss (P); Gadi Wollstein, None
  • Footnotes
    Support  NIH: R01-EY013178
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1248. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mengfei Wu, Mengling Liu, Katie Lucy, Hiroshi Ishikawa, Joel S Schuman, Gadi Wollstein; Applying Propensity Score in Assessing Association of Glaucoma Medication with Structural Progression. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1248.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : When assessing treatment effects in observational studies, the propensity score (PS) method is commonly used to reduce the selection bias of treatments. Weighting subjects by the inverse probability of treatment using the PS mimics treatment randomization. Our goal was to apply PS to assess the association of glaucoma treatment medication with rates of structural changes in a longitudinal cohort of glaucoma subjects.

Methods : Glaucoma subjects treated with prostaglandin, beta blockers, and/or carbonic anhydrase inhibitors (CAIs) with ≥ 2 visits with qualified OCT (Cirrus HD-OCT; Zeiss) were included. Subjects were on medication for at least 3 months prior to each OCT visit. Multinomial PS for baseline medication selection was estimated by baseline age, visual field (VF) mean deviation (MD), intraocular pressure and ethnicity. Rates of change for OCT’s average circumpapillary retinal nerve fiber layer (RNFL) and macular ganglion cell-inner plexiform layer (GCIPL) thicknesses were calculated per eye using linear regression. Their associations with baseline RNFL, GCIPL, baseline medication, post-baseline medication and medication duration were tested using linear regression with and without PS weighting.

Results : 207 eyes (117 subjects) were qualified with average age of 62.2±12.7 years and median MD of -3.6 dB (IQR -9.0, -1.4) at baseline, and a mean follow-up of 3.2±1.8 years. The average duration of treatment range from 1.3±1.8 to 2.4±2.5 years for CAIs and prostaglandin, respectively. At baseline, average RNFL and GCIPL were 71.5±14.4 µm and 65.9±13.5 µm. Throughout follow-up, mean rate of change for RNFL and GCIPL were -0.30±2.60 µm/year and 0.27±7.72 µm/year. Without PS weighting, no medication effect was shown to be associated with either rate of change. With PS weighting, however, the rate of change for RNFL was significantly associated with taking CAIs (-1.26 µm/year, p=0.029) and prostaglandin (-0.98 µm/year, p=0.044) and baseline RNFL (-0.05 µm/year, p=0.017). Longer use of the medications slowed RNFL decrease, although the effects were not statistically significant. No association was detected between treatment and rate of change for GCIPL.

Conclusions : PS can be useful to reduce treatment selection bias and facilitate more rigorous estimation of medication effects in observational glaucoma research.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×